levofloxacin bluefish 250 mg film-coated tablets
bluefish pharmaceuticals ab - levofloxacin - film-coated tablet - 250 milligram(s) - fluoroquinolones; levofloxacin
nevirapine 200mg tablets
wockhardt uk limited - nevirapine anhydrous - tablet - 200 milligram(s) - non-nucleoside reverse transcriptase inhibitors; nevirapine
refaz 500 milligram film coated tablet
pharmathen s.a. - levofloxacin hemihydrate - film coated tablet - 500 milligram - fluoroquinolones
viramune tablet 200 mg
boehringer ingelheim singapore pte. ltd. - nevirapine - tablet - 200 mg - nevirapine 200 mg
viramune xr tablet 400 mg
boehringer ingelheim singapore pte. ltd. - nevirapine anhydrous - tablet, extended release - 400 mg - nevirapine anhydrous 400 mg
nevirapine aurobindo 200mg tablets
aurobindo pharma (malta) limited vault 14, level 2, valletta waterfront, floriana frn 1913, malta - nevirapine - tablet - nevirapine 200 mg - antivirals for systemic use
levofloxacin krka 250 mg film-coated tablets
krka, d.d., novo mesto - levofloxacin hemihydrate - film-coated tablet - 250 milligram(s) - fluoroquinolones; levofloxacin - pharmacotherapeutic group: quinolone antibacterials, fluoroquinolones, - it is indicated in adults for the treatment of the following infections (see sections 4.4 and 5.1): - acute bacterial sinusitis. - acute exacerbations of chronic bronchitis. - community-acquired pneumonia. - complicated skin and soft tissue infections
naproxen tablet, delayed release
stat rx usa llc - naproxen (unii: 57y76r9atq) (naproxen - unii:57y76r9atq) - naproxen 500 mg - carefully consider the potential benefits and risks of naproxen delayed-release tablets and other treatment options before deciding to use naproxen delayed-release tablets. use the lowest effective dose for the shortest duration consistent with individual patient treatment goals (see warnings ). naproxen delayed-release tablets are indicated: - for the relief of the signs and symptoms of rheumatoid arthritis - for the relief of the signs and symptoms of osteoarthritis - for the relief of the signs and symptoms of ankylosing spondylitis - for the relief of the signs and symptoms of juvenile arthritis naproxen as naproxen suspension is recommended for juvenile rheumatoid arthritis in order to obtain the maximum dosage flexibility based on the patient’s weight. naproxen delayed-release tablets are not recommended for initial treatment of acute pain because the absorption of naproxen is delayed compared to absorption from other naproxen-containing products (see clinical pharmacology and dosage and administratio
naproxen tablet, delayed release
h.j. harkins company, inc. - naproxen (unii: 57y76r9atq) (naproxen - unii:57y76r9atq) - naproxen 500 mg - carefully consider the potential benefits and risks of naproxen delayed-release tablets and other treatment options before deciding to use naproxen delayed-release tablets. use the lowest effective dose for the shortest duration consistent with individual patient treatment goals (see warnings ). naproxen delayed-release tablets are indicated: - for the relief of the signs and symptoms of rheumatoid arthritis - for the relief of the signs and symptoms of osteoarthritis - for the relief of the signs and symptoms of ankylosing spondylitis - for the relief of the signs and symptoms of juvenile arthritis naproxen as naproxen suspension is recommended for juvenile rheumatoid arthritis in order to obtain the maximum dosage flexibility based on the patient’s weight. naproxen delayed-release tablets are not recommended for initial treatment of acute pain because the absorption of naproxen is delayed compared to absorption from other naproxen-containing products (see clinical pharmacology and dosage and administratio
naproxen tablet, delayed release
rebel distributors corp - naproxen (unii: 57y76r9atq) (naproxen - unii:57y76r9atq) - naproxen 500 mg - carefully consider the potential benefits and risks of naproxen delayed-release tablets and other treatment options before deciding to use naproxen delayed-release tablets. use the lowest effective dose for the shortest duration consistent with individual patient treatment goals (see warnings ). naproxen delayed-release tablets are indicated: - for the relief of the signs and symptoms of rheumatoid arthritis - for the relief of the signs and symptoms of osteoarthritis - for the relief of the signs and symptoms of ankylosing spondylitis - for the relief of the signs and symptoms of juvenile arthritis naproxen as naproxen suspension is recommended for juvenile rheumatoid arthritis in order to obtain the maximum dosage flexibility based on the patient’s weight. naproxen delayed-release tablets are not recommended for initial treatment of acute pain because the absorption of naproxen is delayed compared to absorption from other naproxen-containing products (see clinical pharmacology and dosage and administratio